An observational study into the maintenance of seroprotection against Meningococcal serogroup C disease throughout childhood following a single dose of a conjugated Meningococcal serogroup C vaccine administered to toddlers - Understanding the persistence of immunity after MenC Vaccines

niversity of Oxford0 个研究点开始时间: 2010年4月16日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Participant whose parent is willing and able to give informed consent for participation in the study.
•Participant who gives assent for participation in the study.
•Male or Female, aged 11 to 13 years.
•Known to be free from medical problems as determined by a medical history and clinical assessment
•Participated in the University of Oxford clinical trial: U01-Td5I-303/ C01.183
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•History of invasive meningococcal C disease
•Any vaccination against MenC disease with the exception of a single dose in 2000 during the nationwide MenC immunisation campaign
•Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection.
•Major congenital defects or serious chronic illness

发起方